@article{a11af3baa7a54b32bcf83e4a9023b9ea,
title = "IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?",
author = "Proksell, \{Siobhan S.\} and Greer, \{Julia B.\} and Theisen, \{Brian K.\} and Davis, \{Peter L.\} and Rosh, \{Joel R.\} and Keljo, \{David J.\} and Alka Goyal and Shah, \{Samir A.\} and Brand, \{Myron H.\} and Herfarth, \{Hans H.\} and Cross, \{Raymond K.\} and Siegel, \{Corey A.\} and Koltun, \{Walter A.\} and Isaacs, \{Kim L.\} and Regueiro, \{Miguel D.\}",
note = "Funding Information: Conflicts of Interest: Julia B. Greer holds a grant from AbbVie. Joel R. Rosh serves as a consultant to and has received grant support from AbbVie and Janssen. Samir A. Shah is on the Speaker{\textquoteright}s Bureau for AbbVie, Janssen, and Takeda. Myron H. Brand serves on the Speakers Bureaus of Abbvie, Gilead, Takeda, and Intercept Pharmaceuticals. Hans H. Herfarth receives consulting fees from Pfizer, Celltrion, Samsung, Merck, and UCB. RaymondK. Cross has participated in Advisory Boards and/or consulting for Janssen, Abbvie, UCB, and Takeda. Corey A. Siegel serves as a consultant to AbbVie, Amgen, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, and UCB, delivered CME activities to American Regent, AbbVie, Janssen, Pfizer, andTakeda, received grant support from AbbVie, Janssen, Pfizer, and Takeda. Kim. L. Isaacs consults on the Data Safety Monitoring Board for Medimmune and Janssen. Miguel D. Regueiro serves on the Advisory Boards and consults for AbbVie, Janssen, Pfizer, Takeda, and UCB. All authors and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Funding Information: Financial Support: Supported by a portion of funding for this work was provided by the Sigal Family Research \& Education Inflammatory Bowel Disease Fund. Funding for the audiovisual conferences, but not for the article, was provided by unrestricted educational grants from AbbVie Inc., Shire US Inc., Takeda Pharmaceuticals Inc., and Pfizer Inc.",
year = "2018",
month = mar,
day = "19",
doi = "10.1093/ibd/izx114",
language = "English (US)",
volume = "24",
pages = "698--713",
journal = "Inflammatory bowel diseases",
issn = "1078-0998",
publisher = "Oxford University Press",
number = "4",
}